Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Operating Leases: 2023-2024

Historic Operating Leases for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $8.0 million.

  • Inhibrx Biosciences' Operating Leases rose 280.82% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 280.82%. This contributed to the annual value of $8.0 million for FY2024, which is 153.64% up from last year.
  • Per Inhibrx Biosciences' latest filing, its Operating Leases stood at $8.0 million for FY2024, which was up 153.64% from $3.2 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Operating Leases ranged from a high of $8.0 million in FY2024 and a low of $3.2 million during FY2023.
  • Its 2-year average for Operating Leases is $5.6 million, with a median of $5.6 million in 2023.
  • Data for Inhibrx Biosciences' Operating Leases shows a peak YoY spiked of 153.64% (in 2024) over the last 5 years.
  • Over the past 2 years, Inhibrx Biosciences' Operating Leases (Yearly) stood at $3.2 million in 2023, then spiked by 153.64% to $8.0 million in 2024.